Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

<p>Eluted tumor-associated antigen-derived peptides.</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Jitske van den Bulk (17142147) (author)
Diğer Yazarlar:	Els M.E. Verdegaal (17142150) (author), Manon van der Ploeg (17142153) (author), Marten Visser (17142156) (author), Joana B. Nunes (17142159) (author), Arnoud H. de Ru (17142162) (author), Rayman T.N. Tjokrodirijo (17142165) (author), Marieke E. Ijsselsteijn (17142168) (author), Natasja I. Janssen (17142171) (author), Ruud van der Breggen (17142174) (author), Linda de Bruin (17142177) (author), Pita de Kok (17142180) (author), George M.C. Janssen (17142183) (author), Dina Ruano (17142186) (author), Ellen H.W. Kapiteijn (17142189) (author), Peter A. van Veelen (17142192) (author), Noel F.C.C. de Miranda (17142195) (author), Sjoerd H. van der Burg (15021483) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Immuno-oncology Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy Skin Cancers Melanoma
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Yazar:: Michael Kilian (16697663)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Yazar:: Michael Kilian (16697663)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Yazar:: Michael Kilian (16697663)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Yazar:: Maria Lozano-Rabella (15056515)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Yazar:: Maria Lozano-Rabella (15056515)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Yazar:: Maria Lozano-Rabella (15056515)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Yazar:: Ankita Mitra (17141783)
Baskı/Yayın Bilgisi: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Yazar:: Ankita Mitra (17141783)
Baskı/Yayın Bilgisi: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Yazar:: Ankita Mitra (17141783)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 5 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Yazar:: Rohit Thummalapalli (17314483)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_b7grjrl1asfjsh9rmv8h4e0sjh